Zenas BioPharma, Inc. (ZBIO) is gearing up to report data from several of its ongoing studies using its differentiated B-Cell targeting drug obexelimab for autoimmune disorders. In particular, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results